GERMANY - DEWB portfolio firm closes alliance with Pfizer

NOXXON Pharma AG has announced the closing of a strategic alliance with Pfizer Inc. NOXXON will, through the exploitation of their proprietary Spiegelmer® Technology, develop product candidates against disease associated Targets identified by Pfizer. Additionally Pfizer and NOXXON have signed a contract concerning an exclusive world-wide licence for the NOXXON Spiegelmer NOX-B11. NOX-B11 is a Ghrelin binding Spiegelmer, which has shown the ability in pre-clinical studies to curb appetite and induce weight loss and shall be developed for the treatment of obesity. NOXXON shall receive upfront payments as well as milestone payments from both agreements. Pfizer will, by means of a capital increase, concurrently make an equity investment in NOXXON.